AstraZeneca Reaps Fruit From BenevolentAI Deal

Kicks Off With Kidney Disease Candidate

 
• By Alexandra Shimmings
  
Generate a summary of this article
Listen to this article
Beta

An artificial intelligence and machine learning deal between BenevolentAI and AstraZeneca struck in 2019 has produced its first drug candidate.    

• Source: Shutterstock

Away from the drama surrounding supply of its COVID-19 vaccine to the EU, AstraZeneca PLCis reaping the first rewards of a 2019 collaboration in artificial intelligence with computational medicines specialist firm BenevolentAI Limited, with the selection of a novel chronic kidney disease (CKD) target to advance into drug development. This will be the first AI-generated target from the collaboration to enter the company’s research portfolio.

The big pharma firm recruited BenevolentAI as part of an initiative to secure future growth using technologies like machine learning...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from AI

AstraZeneca Reaps Fruit From BenevolentAI Deal

 
• By Alexandra Shimmings

An artificial intelligence and machine learning deal between BenevolentAI and AstraZeneca struck in 2019 has produced its first drug candidate.    

More from Digital Technologies

Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends

 
• By Eleanor Malone

From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances

 
• By Eleanor Malone

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.

US Price Control, Outcomes-Based Contracting: Reflections Of Former VA Secretary Shulkin

 
• By Anju Ghangurde

The former Secretary of the US Department of Veterans Affairs, David Shulkin, discusses in an interview with Scrip the US Inflation Reduction Act, telehealth,  interoperability of healthcare data, and Mark Cuban’s pharma venture.